— Know what they know.
Not Investment Advice

PARD OTC

Poniard Pharmaceuticals, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -99.0% 5Y: -99.8%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 51 · $150 mcap · 1M float · 0.0028% daily turnover

Balance Sheet Trends

Total Assets
$12M -77.8% ▼
5Y CAGR: +2.9%
Total Liabilities
$3M -88.9% ▼
5Y CAGR: -14.4%
Shareholders Equity
$8M -64.2% ▼
5Y CAGR: +21.6%
Cash & Investments
$4M -90.0% ▼
5Y CAGR: +4.2%
Total Debt
$2M -92.2% ▼
5Y CAGR: -16.5%
Net Debt
$290K -93.3% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2006FY2007FY2008FY2009FY2010
— Assets —
Cash$44M$29M$44M$16M$1M
Short-Term Investments$10M$63M$29M$27M$3M
Cash & ST Investments$54M$93M$73M$43M$4M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$136K$281K$281K$281K$158K
Total Current Assets$54M$94M$74M$44M$5M
Property, Plant & Equip.$525K$1M$1M$219K$49K
Goodwill & Intangibles$11M$10M$9M$8M$6M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$3M$141K$289K$135K$0
Total Non-Current Assets$15M$11M$10M$8M$6M
Total Assets$69M$105M$84M$52M$12M
— Liabilities —
Accounts Payable$775K$677K$604K$849K$392K
Short-Term Debt$4M$4M$8M$9M$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$5M$0-$32K$7M$1M
Total Current Liabilities$12M$9M$19M$17M$2M
Long-Term Debt$10M$7M$17M$10M$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$10M$7M$17M$12M$2M
Total Liabilities$22M$16M$37M$29M$3M
— Equity —
Common Stock$456K$693K$694K$842K$971K
Retained Earnings-$280M-$313M-$362M-$408M-$439M
Accumulated OCI$0$0-$354K-$17K$8K
Total Stockholders Equity$47M$89M$48M$24M$8M
Total Liabilities & Equity$69M$105M$84M$52M$12M
— Key Metrics —
Total Debt$14M$11M$25M$20M$2M
Net Debt-$30M-$19M-$19M$4M$290K
Total Investments$10M$63M$29M$27M$3M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms